Situation Report

NEW BRUNSWICK, New Jersey, Aug. 5, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).

So far, most of the conversation about COVID-19 vaccines has focused on the question of whether researchers can develop an effective vaccine in record time. 

But maybe we should start asking another question as well: Will enough Americans actually get the vaccine for it to be effective? 

“It’s not a vaccine that will save us,” says Harvard Global Health Institute director Ashish Jha. “It’s vaccination.”